Healthcare

HR 5592, the Childhood Genital Mutilation Prevention Act, prohibits medical procedures related to gender identity for minors under 18, with exceptions for treating specific medical conditions like disorders of sex development or injuries. It criminalizes performing such treatments under certain circumstances (e.g., involving interstate commerce) with penalties up to 10 years in prison, while exempting care for diagnosed medical needs. The bill also excludes these procedures from Medicare/Medicaid coverage after 90 days and bans federal funding for such treatments or related health coverage. This directly affects minors under 18, healthcare providers, and insurers offering these services, but allows exceptions for medically necessary care.

Repair Abuses of MSP Payments Act or the RAMP Act This bill restricts the private right of action against insurance plans that do not provide appropriate primary payment in cases in which Medicare is a secondary payer. Current law allows for a private right of action against primary plans that do not provide appropriate primary payment in cases in which Medicare is a secondary payer; this provision applies to group health plans, workers' compensation plans, automobile or liability insurance plans, and no-fault insurance plans. The bill limits this provision to group health plans.

S 2702 requires K-12 schools receiving federal funds to obtain parental consent before accommodating students' gender identity expressions that differ from their biological sex. It prohibits schools from hiding such information from parents, encouraging students to conceal gender identity concerns, or facilitating referrals for gender transition procedures without consent. Schools must publicly post compliance policies and provide written policies to families, with violations allowing parents to sue for injunctive relief, attorney fees, and compensation for "harm" from gender transition treatments. The bill directly affects school districts, staff, and families of students under 18, mandating parental involvement in decisions about gender identity accommodations.

This bill redirects federal funding toward mandatory treatment facilities for unhoused individuals with serious mental illness or addiction, while tying grant money to local enforcement of public drug use bans, camping restrictions, and sex offender registration. It prohibits federal support for "harm reduction" programs and safe consumption sites, requires states to prioritize treatment over "housing first" approaches, and mandates data sharing between health programs and law enforcement. The bill defines "unhoused individuals" as those posing public risks or unable to care for themselves for 3+ months. It applies to federal grant programs for homelessness services, mental health treatment, and housing assistance.

HR 5629 would prevent the Department of Health and Human Services' final rule on opioid treatment medications from taking effect, except for changes to accreditation standards for opioid treatment programs. The rule, published in February 2024, aimed to expand access to certain medications for opioid use disorder by modifying treatment protocols. This bill would maintain current regulations for medication-assisted treatment by blocking the rule's implementation, while leaving accreditation requirements unchanged. As a result, existing treatment guidelines would remain in place, but program accreditation standards would still be updated per the rule's exception.

The Jobs and Opportunities for Medicaid Act would require most Medicaid recipients aged 18 to 65 to work or volunteer at least 20 hours per week (averaged monthly) to maintain health coverage, starting January 1, 2026. Exemptions include individuals who are pregnant, primary caregivers for children under 6, medically unable to work, or enrolled in substance abuse treatment programs. States would need to verify each month whether recipients meet this work requirement to continue receiving Medicaid benefits.

The MOSSA Act (HR 4878) directs federal agencies to prioritize funding for local governments enforcing laws against public drug use, camping, and loitering, while requiring homelessness programs to link participants with mental health/substance use treatment as a condition of aid. It mandates that federal grant programs for homelessness services end support for "housing first" approaches and "harm reduction" initiatives, instead requiring evidence-based treatment programs and stricter accountability for service providers. The bill also directs agencies to address sex offenders in homeless programs by restricting their housing with children and to review funding recipients operating drug injection sites for legal violations. These provisions collectively shift federal funding toward enforcement-focused and treatment-oriented homelessness strategies, affecting state/local governments, homeless service providers, and individuals accessing federal housing assistance.

This bill would pause most visa issuances and immigration status approvals until specific conditions are met under immigration law. It prohibits access to public schools for unauthorized immigrants, restricts citizenship eligibility to children born in the U.S. with at least one U.S. citizen or permanent resident parent, and bars certain benefits like Medicare, food assistance, and student loans for most non-citizens. The bill also imposes a $100,000 fee on H-1B work visa applications starting in 2026, terminates the Optional Practical Training program for international students, and repeals the Diversity Visa lottery program. These provisions directly affect immigrants seeking visas, students, and applicants for specific immigration pathways.

# Summary of the Financial Services and General Government Appropriations Act, 2026 This Act provides funding for various federal agencies and departments under the Financial Services and General Government Appropriations category for fiscal year 2026. The legislation contains over 750 sections with detailed provisions governing how funds may be used, restrictions on certain activities, and requirements for transparency and reporting. Key provisions include: 1. **Restrictions on Healthcare Coverage**: Prohibits funds for gender-affirming care in the Federal Employees Health Benefits program (Section 761) and limits abortion coverage except in cases where the mother's life is endangered or the pregnancy resulted from rape or incest (Sections 809, 818). 2. **Executive Compensation Limits**: Imposes restrictions on pay increases for senior executive positions, including Executive Schedule positions (Sections 737-746), with specific provisions preventing pay rate increases for certain positions during calendar year 2026. 3. **District of Columbia Provisions**: Contains numerous restrictions on how District of Columbia funds may be spent, including prohibitions on: - Enforcing certain abortion-related laws (Section 818) - Implementing certain voting rights or criminal justice reforms (Sections 825, 827) - Legalizing recreational marijuana (Section 830) - Enforcing certain environmental regulations (Section 821) 4. **Prohibitions on Certain Activities**: - Bans implementation of certain executive orders related to voting access (Section 756) - Prohibits funds for vaccine or mask mandates (Section 757) - Restricts funding for entities that engage in "fact-checking" or credibility rating of news outlets (Section 758) - Prohibits funding for certain types of research or medical procedures 5. **Transparency Requirements**: Mandates detailed reporting on conference costs, travel expenses, and other expenditures (Section 738). The Act serves as a comprehensive funding measure for financial services and general government operations while embedding numerous policy restrictions on how those funds may be used across federal agencies and the District of Columbia.

HR 1463 prohibits the use of federal funds to implement, administer, or enforce a specific FDA rule about medical devices known as "laboratory developed tests" (LDTs), published in the Federal Register on May 6, 2024 (89 Fed. Reg. 37286). The bill directly affects the Food and Drug Administration (FDA), preventing it from using taxpayer money to carry out this regulation. Its key mechanism is a straightforward funding ban on the specified rule and any substantially similar future rule. This is a procedural restriction focused solely on blocking financial support for the FDA's LDT regulatory approach.